ReviewFrontiers in immunology2026
Epithelial-mesenchymal transition in cutaneous fibrosis disease: from mechanisms to therapy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cutaneous fibrosis takes place due to chronic inflammation, tissue trauma, or autoimmune reactions. It is marked by abnormal tissue remodeling; such remodeling is characterized by a raised quantity of myofibroblasts and an excessive accumulation of extracellular matrix (ECM) in the dermis. Therefore, this abnormal process brings about a decrease in tissue function, causes structural irregularities, and thus severely lowers patients' quality of life. Although remarkable progressions have been achieved in preventive and treatment methods, the molecular processes under cutaneous fibrosis are not fully comprehended. Epithelial-mesenchymal transition (EMT) is a dynamic and strictly controlled biological phenomenon where epithelial cells discard their epithelial characteristics and obtain mesenchymal properties. Hence, newly appearing data has demonstrated that EMT plays a critical role in the development of fibrotic disorders. EMT has been proposed as a potential contributor to fibrogenesis, although its quantitative contribution and pathological significance relative to resident fibroblasts and other mesenchymal cell sources remain to be further clarified. These findings not only increase our knowledge of the pathophysiology of cutaneous fibrosis but also identify new molecular targets that can be utilized for therapeutic aims. This review collects the latest progressions in understanding the role of EMT in cutaneous fibrotic disorders. The objective is to provide new understandings into the regulatory mechanisms and possible treatment ways for this condition.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.